Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Growth Projections For The T Cell Specific Surface Glycoprotein CD28 Market Size During 2025–2029?
The market for T cell-specific surface glycoprotein CD28 has witnessed rapid expansion in recent years. It is anticipated to increase from $1.47 billion in 2024 to $1.62 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.1%. The historical development of this market can be attributed to factors like heightened research in immunotherapy, the escalating prevalence of cancer, an increase in autoimmune disease cases, a rise in clinical trials, and the growing adoption of monoclonal antibodies.
The T cell-specific surface glycoprotein CD28 market is anticipated to exhibit significant growth over the next few years, with its size projected to reach $2.35 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.8%. This expansion during the forecast period is propelled by factors such as an escalating demand for personalized medicine, an increasing focus on T-cell-based therapies, rising awareness surrounding immuno-oncology, an expanding pipeline of targeted therapies, growing investments from pharmaceutical companies, and broader applications in chronic diseases. Prominent trends observed for the forecast period include advancements in cell engineering technologies, sophisticated development of bispecific antibodies, innovations in targeted immunotherapies, the integration of AI within drug discovery, and improvements in the manufacturing of biologics.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp
Which Industry Drivers Are Expected To Accelerate The T Cell Specific Surface Glycoprotein CD28 Market From 2025 To 2029?
An increasing focus on personalized medicine is anticipated to drive the expansion of the T cell-specific surface glycoprotein CD28 market in the future. This medical strategy involves customizing treatments for individual patients, considering their genetic, environmental, and lifestyle elements to achieve better results and enhance care. Demand for personalized medicine is rising, propelled by progress in genomic technologies that facilitate accurate identification of genetic differences and allow for individualized therapeutic approaches. T cell-specific surface glycoprotein CD28 contributes to personalized medicine by allowing for targeted immune system adjustments, thus making treatments more accurate and potent. It improves therapeutic results through fostering optimal T cell activation, which in turn enhances immune responses tailored to specific patients. For example, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit group, indicated that the U.S. Food and Drug Administration (FDA) cleared 26 new personalized medicines in 2023, a significant rise from the 12 approved in 2022. Consequently, the increasing focus on personalized medicine is fueling the expansion of the T cell-specific surface glycoprotein CD28 market.
How Is The T Cell Specific Surface Glycoprotein CD28 Market Segmented?
The t cell specific surface glycoprotein cd28 market covered in this report is segmented
1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types
2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry
3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers
4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research
5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories
Subsegments:
1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships
2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations
3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering
4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds
Which Market Trends Are Creating New Opportunities In The T Cell Specific Surface Glycoprotein CD28 Industry?
Leading companies in the T cell-specific surface glycoprotein CD28 market are concentrating on developing innovative products, such as combination immunotherapies, to enhance T cell activation, improve anti-tumor efficacy, and better patient treatment outcomes. Combination immunotherapies are treatments that integrate multiple immune-based approaches to strengthen the body’s ability to combat disease. For instance, in February 2025, Rondo Therapeutics Inc., a US-based biopharmaceutical company, unveiled preclinical data on RNDO 564, a novel CD28 Nectin 4 costimulatory bispecific antibody intended for advanced bladder cancer. It is specifically engineered to selectively activate CD28 on T cells upon interaction with Nectin-4-expressing tumor cells, thereby boosting T-cell-mediated tumor killing while minimizing off-target toxicity. The data demonstrated potent anti-tumor activity in preclinical models, lending support for its further development as a potential therapy for patients with metastatic urothelial carcinoma.
Which Key Market Players Are Investing In Expansion And Innovation Of T Cell Specific Surface Glycoprotein CD28 Market?
Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.
Download The Full Report For Exclusive Market Findings:
Which Region Shows The Highest Potential For Future Expansion In The T Cell Specific Surface Glycoprotein CD28 Market?
North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The T Cell Specific Surface Glycoprotein CD28 Market Report:
https://www.thebusinessresearchcompany.com/customise?id=27429&type=smp
Browse Through More Reports Similar to the Global T Cell Specific Surface Glycoprotein CD28 Market 2025, By The Business Research Company
Monitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/monitor-global-market-report
Display Monitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/display-monitor-global-market-report
Holter Monitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/holter-monitor-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model